Money Is Moving

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Public market insider selling at Aurinia Pharmaceuticals (T:AUP)

Updated Monday Jul 27, 2020 05:18 AM EDT

Chin Kyu Huh, a 10% Holder, disposed of 600,000 Common Shares on a control or direction basis for registered holder ILJIN SNT Co., Ltd. at a price of $16.408USD on July 22nd, 2020. This represents a $13,211,722 divestment of the company's shares and an account share holdings change of -6.7%.

Aurinia Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Voclosporin is a calcineurin inhibitor (CNI). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney.

INK Edge Outlook

CONDITIONS:
Latest
6 months ago
1 year ago
Overall
Rain
Mixed
Cloudy
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at inkresearch.com.
Two-week free trial for first time users.
Go to Aurinia Pharmaceuticals Inc. (AUP)'s company page

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Comment On!

No Comments

Twitter

Search (past week) for $AUP.CA

Stocktwits